Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

NOVATO, Calif., May 10, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 16, 2017 at 3:00 pm PT in Las Vegas, NV.

The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Ryan Martins	
844-758-7273